Pembrolizumab and palliative radiotherapy in 2 cases of refractory mycosis fungoides
Authors:
Open Access
- 1 January 2021
- journal article
- Published by Elsevier in JAAD Case Reports
- Vol. 7, 87-90
Abstract
No abstract availableKeywords
This publication has 13 references indexed in Scilit:
- Outcome of allogeneic hematopoietic stem cell transplantation for mycosis fungoides and Sézary syndromeHematological Oncology, 2020
- Pembrolizumab in Relapsed and Refractory Mycosis Fungoides and Sézary Syndrome: A Multicenter Phase II StudyJournal of Clinical Oncology, 2020
- Phase II Trial of Ipilimumab with Stereotactic Radiation Therapy for Metastatic Disease: Outcomes, Toxicities, and Low-Dose Radiation–Related Abscopal ResponsesCancer Immunology Research, 2019
- Immunotherapy for Cutaneous T-Cell Lymphoma: Current Landscape and Future DevelopmentsJournal of Cutaneous Medicine and Surgery, 2019
- Radiotherapy induces responses of lung cancer to CTLA-4 blockadeNature Medicine, 2018
- Primary T Cells from Cutaneous T-cell Lymphoma Skin Explants Display an Exhausted Immune Checkpoint ProfileCancer Immunology Research, 2018
- Safety and Clinical Activity of Pembrolizumab and Multisite Stereotactic Body Radiotherapy in Patients With Advanced Solid TumorsJournal of Clinical Oncology, 2018
- Keytruda (Pembrolizumab): First PD-1 Inhibitor Approved for Previously Treated Unresectable or Metastatic Melanoma.2015
- Long-Term Outcome of Allogeneic Hematopoietic Cell Transplantation for Patients With Mycosis Fungoides and Sézary Syndrome: A European Society for Blood and Marrow Transplantation Lymphoma Working Party Extended AnalysisJournal of Clinical Oncology, 2014
- A Meta-analysis of Patients Receiving Allogeneic or Autologous Hematopoietic Stem Cell Transplant in Mycosis Fungoides and Sézary SyndromeTransplantation and Cellular Therapy, 2009